IP Library Granted Patent US 8,461,102
Granted Patent B2
US 8,461,102 · App. 13/343,515 · Granted Jun 11, 2013

Methods and compositions for treating and preventing symptoms of hormonal variations

Inventor: George E. Royster, Jr. (Greenville, NC)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,461,102
App. No.
13/343,515
Granted
Jun 11, 2013
Kind
B2
Abstract

The present invention relates to methods, compositions, and kits for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of Dextromethorphan or Dextrorphan, or a pharmaceutically acceptable salt thereof, to a subject having one or more symptoms of hormonal variations.

Claims (15)

1. A method for treatment of symptoms of hormonal variation, comprising:

Identifying a subject having one or more symptoms of hormonal variations resulting in hot flashes and night sweats;

administering to the subject an effective amount of Dextromethorphan or Dextrorphan, or a pharmaceutically acceptable salt thereof, in a controlled-release or a sustained-release dosage form.

2. The method of claim 1 wherein said Dextromethorphan is DextromethorphanHBr.

3. The method of claim 1 wherein the effective amount of Dextromethorphan or Dextrorphan is from 0.1 to 120 mg per day.

4. The method of claim 1 wherein the subject is a female.

5. The method of claim 1 wherein the subject is a male.

6. The method of claim 1 further comprising administering an effective amount of Dextromethorphan or Dextrorphan, or a pharmaceutically acceptable salt thereof, through a transdermal patch.

7. A method for treatment of symptoms of hormonal variation, comprising:

identifying a subject having one or more symptoms of hormonal variations resulting in hot flashes and night sweats;

administering to the subject an effective amount of Dextromethorphan or Dextrorphan, or a pharmaceutically acceptable salt thereof, and another compound known to reduce the symptoms of hormonal variation in a controlled-release or sustained-release dosage form.

8. The method of claim 7 , wherein the another compound known to reduce the symptoms of hormonal variation is selected from the group consisting of a conjugated estrogen, bupropian, venlafaxine, fluoxetine, duloxetine, sertraline, clonidine, clonidine hydrochloride, methyldopa, and gabapentin.

9. The method of claim 8 wherein said another compound is gabapentin.

10. The method of claim 8 wherein the amount of Dextromethorphan or Dextrorphan administered is from 0.1 to 120 mg per day and the amount of gabapentin administered is from 1 mg to 900 mg per day.

11. The method of claim 1 further comprising administering an effective amount of Dextromethorphan or Dextrorphan, or a pharmaceutically acceptable salt thereof, and another compound known to reduce or prevent the symptoms of hormonal variation through a transdermal patch.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE NAME OF THE ASSIGNEE FROM WORDSWORTH, STEVE JONES TO WORDSWORTH, STEVE. PREVIOUSLY RECORDED ON REEL 74737 FRAME 405. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 25, 2026
From: FERVENT PHARMACEUTICALS, LLC
To: WORDSWORTH, STEVE
Reel/Frame 075625/0415 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2026
From: FERVENT PHARMACEUTICALS, LLC
To: WORDSWORTH, STEVE JONES
Reel/Frame 074737/0405 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2026
From: WORDSWORTH, STEVE
To: KUULNG, LLC
Reel/Frame 074737/0415 →
RELEASE OF SECURITY INTEREST Recorded Apr 20, 2016
From: WARD AND SMITH, P.A.
To: FERVENT PHARMACEUTICALS, LLC
Reel/Frame 038332/0647 →
SECURITY INTEREST Recorded Oct 22, 2014
From: FERVENT PHARMACEUTICALS, LLC; ROYSTER, GEORGE
To: WARD AND SMITH, P.A.
Reel/Frame 034010/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2012
From: ROYSTER, JR., GEORGE E.
To: FERVENT PHARMACEUTICALS, LLC
Reel/Frame 027827/0213 →
Continuity (3)
Continuation In Part 13037728 · Mar 1, 2011
Provisional Application 61309638 · Mar 2, 2010
Related Publication 20120156301A1 · Jun 21, 2012